Recent Investment Analysts’ Ratings Updates for PROCEPT BioRobotics (PRCT)
by Doug Wharley · The Cerbat GemPROCEPT BioRobotics (NASDAQ: PRCT) recently received a number of ratings updates from brokerages and research firms:
- 7/2/2026 – PROCEPT BioRobotics had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $25.00 price target on the stock, down from $30.00.
- 7/2/2026 – PROCEPT BioRobotics was downgraded by Citigroup Inc. to “hold”.
- 6/24/2026 – PROCEPT BioRobotics is now covered by Evercore Inc. They set an “outperform” rating and a $30.00 price target on the stock.
- 6/24/2026 – PROCEPT BioRobotics was upgraded by Evercore Inc to “strong-buy”. They now have a $30.00 price target on the stock.
- 6/11/2026 – PROCEPT BioRobotics was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $29.00 price target on the stock, down from $31.00.
PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.
The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.